Farquhar John C.M. sold $1.4M of HTFL

Farquhar John C.M. (Chief Executive Officer) sold 38,900 shares of Heartflow, Inc. (HTFL) at $35.00 ($1.36M total) on 2026-06-24 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Farquhar John C.M.
Published Jun 26, 2026, 10:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 26, 2026, 10:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$HTFL
Neutral
medium confidence
Mentioned
$HTFL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HTFLNeutralLow
01

Why it matters

The newest actionable element is the disclosed sale size ($1.36M) and execution details (38,900 shares at $35.00) under a 10b5-1 plan; this can influence short-term sentiment but does not change fundamentals by itself.

02

Market read

Traders may monitor HTFL for sentiment drift around insider activity, but the 10b5-1 structure limits interpretive weight.

03

What to watch

The filing provides post-transaction share count and exact execution price, but it does not disclose reasons for sale or any concurrent operational updates.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-26 after-hours; reflects sale executed 2026-06-24.

Background

The article is an SEC Form 4 insider transaction disclosure for Heartflow, Inc. (HTFL).

Company-level read

Ticker impact

$HTFLNeutralMedium confidence
Context

Heartflow CEO Farquhar sold 38,900 shares at $35.00/share under a pre-arranged 10b5-1 plan, disclosed via Form 4.

Expected impact

Likely limited/short-lived impact; any reaction would be sentiment-driven rather than a new business catalyst.

Evidence & confidence

The filing is primary-source and time-stamped, but it is an open-market sale under a 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide regulatory/product change.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, it may be routine liquidity rather than a bearish signal; traders may ignore it unless paired with other negative catalysts.

Key entities

  • Heartflow, Inc.

    Subject of the Form 4 insider transaction; CEO Farquhar sold shares under a 10b5-1 plan.

  • Farquhar John C.M.

    CEO and officer/director who executed the open-market sale disclosed in the filing.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

HeartFlow: 3 Key Takeaways for Long-Term Investors

HeartFlow reported revenue growth outpacing expenses, narrowing operating losses. The company has $253M in cash and expects to achieve positive cash flow by mid-2028. It aims for an 85% non-GAAP gross margin and is expanding its platform with new products like PCI Navigator. Management highlights structural advantages and growing clinical evidence.

$HTFLHighAI 8/10

HeartFlow (HTFL) Q3 2026 Earnings Call Transcript

HeartFlow (HTFL) reported Q3 2026 revenue of $72.9M, up 57% YoY, driven by Plaque adoption and FFRCT utilization. They raised full-year revenue guidance to $262M-$264M, up 49%-50% YoY. Non-GAAP gross margin guidance was increased to 82.5%, with midterm profitability goals reaffirmed. Commercial adoption and clinical evidence support growth.

$HTFLMedAI 8/10

What Heartflow (HTFL) Said on Its Q3 Earnings Call

Heartflow (HTFL) expects to reach cash flow profitability by mid-2028, with declining operating expenses and narrowing losses. The company anticipates 1,300 Plaque Analysis-activated accounts by year-end and 37% year-over-year FFRct volume growth in Q4. Plaque Analysis pricing is expected to be flat sequentially, with a 10% increase in Q1 2027. Clinical data shows Plaque Analysis reduces major cardiovascular events and heart attack rates.